Lanreotide

FDA Approved: * December 17, 2021
Pharm Company: * INVAGEN PHARMS
Category: Acromegaly

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for s... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection
NDC: 69097-870
Labeler:
Cipla USA Inc.
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection
NDC: 69097-880
Labeler:
Cipla USA Inc.
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection
NDC: 69097-890
Labeler:
Cipla USA Inc.
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection
NDC: 76282-709
Labeler:
Exelan Pharmaceuticals, Inc.
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection
NDC: 76282-710
Labeler:
Exelan Pharmaceuticals, Inc.
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection
NDC: 76282-711
Labeler:
Exelan Pharmaceuticals, Inc.

Related Brands

Drugs with the same active ingredients